Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Cash from Financing Activities (2016 - 2025)

Organogenesis Holdings (ORGO) has 10 years of Cash from Financing Activities data on record, last reported at -$4.8 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 114.29% year-over-year to -$4.8 million; the TTM value through Dec 2025 reached -$17.4 million, down 162.81%, while the annual FY2025 figure was -$17.4 million, 162.81% down from the prior year.
  • Cash from Financing Activities reached -$4.8 million in Q4 2025 per ORGO's latest filing, up from -$10.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $33.6 million in Q4 2024 and bottomed at -$10.2 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $76850.0, with a median of -$1.1 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: plummeted 5630.77% in 2023, then skyrocketed 1993.58% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$917000.0 in 2021, then crashed by 104.47% to -$1.9 million in 2022, then grew by 5.23% to -$1.8 million in 2023, then surged by 1993.58% to $33.6 million in 2024, then tumbled by 114.29% to -$4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$4.8 million in Q4 2025, -$10.2 million in Q3 2025, and -$288000.0 in Q2 2025.